Pittsburgh, March 27, 2001 -- Neuro-oncologists at the Brain Tumor Center and the University of Pittsburgh Cancer Institute are participating in a national trial of STI-571 for recurrent malignant gliomas and meningiomas. STI-571 has recently garnered attention for its ability to induce remissions in patients with chronic myelogenous leukemia.

This oral medication will be evaluated in a study to identify the tolerability and effectiveness in recurrent brain tumors. This study is being conducted through the North American Brain Tumor Consortium.

For additional information, please contact the principal investigator David Schiff, MD, at (412) 692-2600 or the clinical research coordinator Mark Wargo, RN, at (412) 647-5369